Quintrigen · raw details

Quintrigen is developing p53, a targeted anti-cancer and tumor suppressor drug. The company has identified a family of small peptides that can reeducate mutant p53 to do its job. In pre-clinical models, these peptides have been shown to reactivate a wide variety of different mutant p53 proteins by refolding the mutant p53 to its natural native conformation and restoring its potent wild-type functionality, including the capability to induce cancer cell death. The treatment is shown to be highly selective against cancer cells, sparing normal cells and tissues. Quintrigen is a joint venture of the Weizmann institute in Israel and South Korean biotech Bioleaders.